Summary

Vernakalant in hospital emergency practice: safety and effectiveness

Carbajosa Dalmau J, Cosín-Sales J, Pérez-Durá MJ, Noceda J, Urtubia-Palacios A, Hernández-Sori N, Peiró-Gómez A, Jacob J, Llorens P, Ruescas-Gómez L, Martín-Martínez A


Affiliation of the authors

Servicio Urgencias,Hospital General de Alicante; Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL-Fundación FISABIO), Alicante, Spain. Grupo de Arritmias Cardiacas, SEMES. Servicio Cardiología, Hospital Arnau de Villanova, Valencia, Spain. Servicio Urgencias, Hospital Universitario y Politécnico La Fe, Valencia, Spain. Servicio Urgencias, Hospital de Sagunto, Valencia, Spain. Servicio Urgencias, Hospital de Elda, Alicante, Spain. Servicio Urgencias, Hospital Arnau de Villanova, Valencia, Spain. Servicio de Urgencias, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain. Servicio de Urgencias, Unidad de Corta Estancia y Hospitalización a Domicilio, Hospital General de Alicante; Departamento de Medicina Clínica, Universidad Miguel Hernández; Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL-Fundación FISABIO), Alicante, Spain. Servicio Urgencias, Hospital Universitario Severo Ochoa, Madrid, Spain.

DOI

Quote

Carbajosa Dalmau J, Cosín-Sales J, Pérez-Durá MJ, Noceda J, Urtubia-Palacios A, Hernández-Sori N, et al. Vernakalant in hospital emergency practice: safety and effectiveness. Emergencias. 2017;29:397-402

Summary

Objectives.

To study the effectiveness and safety of vernakalant for restoration of sinus rhythm in patients with atrial fibrillation (AF) in routine hospital emergency department care, and to evaluate factors associated with a more effective response.

Methods.

Prospective multicenter cohort study enrolling consecutive patients who were administered vernakalant for medical cardioversion of AF between September 2014 through March 2016 in 5 hospitals in the Spanish autonomous community of Valencia.

Results.

We studied 165 cases. The median (interquartile range) was 68 years (56–77) years. Cardioversion with vernakalant was effective in 77.6% (95% CI, 71.1%–84%). The median time to conversion was 8 ( 6–12) minutes after a first dose and 34 (22–62) minutes after a second dose. A prior history of cardiac insufficiency was nonsignificantly less

common in patients who converted with vernakalant (6.3%) than in those who did not (18.9%) (adjusted odds ratio [OR], 0.45 [95% CI, 0.13–1.56]; P=.208). Having no prior history of AF was nonsignificantly related to greater effectiveness (in 54.7% vs in 35.1% with prior AF). Duration less than 12 hours was significantly associated with greater effectiveness (83.6% vs 59.5%; adjusted OR, 2.76 [95% CI, 1.12–6.80]; P=.028). Adverse events were reported for 30 patients. None of the events had clinically important consequences, and in only 2 cases (1.2%) was it necessary to suspend treatment.

Conclusion. Vernakalant is effective and safe for restoring sinus rhythm in the hospital emergency department.

 

More articles by the authors

Leave a Reply

Your email address will not be published. Required fields are marked *

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.